In particular, the phase II/III trial NCT04167293 (ISBRT01) is evaluating this type of local treatment in association with sintilimab (a monoclonal antibody anti-PD1) in an advanced stage of HCC. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.